key: cord-0997772-v8wygcxt
authors: Pacheco-Olvera, Diana Laura; Remy-Hernández, Stephanie Saint; Acevedo-Ochoa, Ernesto; Arriaga-Pizano, Lourdes; Cérbulo-Vázquez, Arturo; Ferat-Osorio, Eduardo; Rivera-Hernández, Tania; López-Macías, Constantino
title: Bioinformatic analysis of shared B and T cell epitopes amongst relevant coronaviruses to human health: Is there cross-protection?
date: 2020-07-15
journal: bioRxiv
DOI: 10.1101/2020.07.14.202887
sha: 15903ad934db6e87cbcb6b68f890e3401d61e5c8
doc_id: 997772
cord_uid: v8wygcxt

Within the last 30 years 3 coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2, have evolved and adapted to cause disease and spread amongst the human population. From the three, SARS-CoV-2 has spread world-wide and to July 2020 it has been responsible for more than 11 million confirmed cases and over half a million deaths. In the absence of an effective treatment or vaccine, social distancing has been the most effective measure to control the pandemic. However it has become evident that as the virus spreads the only tool that will allow us to fully control it is an effective vaccine. There are currently more than 150 vaccine candidates in different stages of development using a variety of viral antigens, with the S protein being the most targeted antigen. Although some new experimental evidence suggests cross-reacting responses between coronaviruses are present in the population, it remains unknown whether potential shared antigens between different coronaviruses could provide cross-protection. Given that coronaviruses are emerging pathogens and continue to represent a threat to global health, the development of a SARS-Cov-2 vaccine that could provide ‘universal’ protection against other coronaviruses should be pushed forward. Here we present a thorough review of reported B and T cell epitopes shared between SARS-CoV-2 and other relevant coronaviruses, in addition we used web-based tools to predict novel B and T cell epitopes that have not been reported before. Analysis of experimental evidence that is constantly emerging complemented with the findings of this study allow us support the hypothesis that cross-reactive responses, particularly those coming from T cells, might play a key role in controlling infection by SARS-CoV-2. We hope that with the evidence presented in this manuscript we provide arguments to encourage the study of cross-reactive responses in order to elucidate their role in immunity to SARS-CoV-2. Finally we expect our findings will aid targeted analysis of antigen-specific immune responses and guide future vaccine design aiming to develop a cross reactive effective vaccine against respiratory diseases caused by coronaviruses.

Within the last 30 years 3 coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2, have evolved 17 and adapted to cause disease and spread amongst the human population. From the three, SARS-CoV-18 2 has spread world-wide and to July 2020 it has been responsible for more than 11 million confirmed 19 cases and over half a million deaths. In the absence of an effective treatment or vaccine, social 20 distancing has been the most effective measure to control the pandemic. However it has become 21 evident that as the virus spreads the only tool that will allow us to fully control it is an effective 22

vaccine. There are currently more than 150 vaccine candidates in different stages of development 23 using a variety of viral antigens, with the S protein being the most targeted antigen. Although some 24 new experimental evidence suggests cross-reacting responses between coronaviruses are present in 25 the population, it remains unknown whether potential shared antigens between different 26 coronaviruses could provide cross-protection. Given that coronaviruses are emerging pathogens and 27 continue to represent a threat to global health, the development of a SARS-Cov-2 vaccine that could 28 provide 'universal' protection against other coronaviruses should be pushed forward. Here we present 29 a thorough review of reported B and T cell epitopes shared between SARS-CoV-2 and other relevant 30

coronaviruses, in addition we used web-based tools to predict novel B and T cell epitopes that have 31 not been reported before. Analysis of experimental evidence that is constantly emerging 32

complemented with the findings of this study allow us support the hypothesis that cross-reactive 33 1

Introduction (3034 words) 41

At the end of December 2019, the Chinese government emitted a sanitary alert regarding a novel 42 coronavirus which was responsible of a significant number of severe respiratory infections. SARS-43

CoV-2 was identified as the etiological agent causing what was later designated as coronavirus 44

disease . Until July 2020, SARS-CoV-2 has caused more than 11 million confirmed 45

infections and over half a million deaths world-wide (1 interaction with wildlife is key in the evolution of these coronaviruses, thus it is expected that more 53 outbreaks of emergent viruses as such will continue to occur in the future, representing a constant 54 threat to human health (4). On the other hand, other human coronaviruses, HCoV-HKU1 (HKU), 55

HCoV-NL63 (NL63), HCoV-OC43 (OC43) and HCoV-229E (229E), circulate amongst the human 56 population in a seasonal manner causing non-severe respiratory disease (2). Immune responses 57 against infections with outbreak or seasonal coronaviruses differ significantly. Evidence suggests that 58 immunity to seasonal coronaviruses is short-lasting with antibodies quickly decreasing after infection 59 (5) , and controlled infection of human volunteers suggests infection does not generate protective 60 immunity against re-infection (6). On the other hand, it has been reported that patients who recovered 61 from infection with SARS-CoV carry circulating antibodies up to 12 years after the infection 62 occurred, although the neutralising activity of such antibodies was not investigated (7). 63

As the current pandemic unfolds, it has become evident that the only tool that will allow humanity to 64 control the virus spread is the development of a safe and effective vaccine. attention has been given to study T cell responses and their role in protection (9, 10). Here we present 74 a compilation of potential B and T cell epitopes found in the SARS-CoV-2 spike glycoprotein and 75 discuss their potential role in generating cross-reactive immune responses against other human 76 coronaviruses. We aim that this study will support and strengthen the hypothesis that T cell responses 77 play a key role in immunity to SARS-CoV-2 including pre-existing responses to other seasonal 78 coronaviruses. In addition we hope that the epitope compilation will aid the rational design of a 79 vaccine that could provide cross-protection against other coronaviruses that currently circulate 80 amongst the human population or even other coronaviruses that might emerge in the future from 81 other animal species with pandemic potential. binding values of <50 (high affinity) and <500 (medium affinity). In order to determine if the 95 predicted B cell epitopes were exposed in the protein surface, the surface accessibility and secondary 96 structure, NetSurfP-2.0 was used (13). Prediction of conformational B cell epitopes was performed 97

using Results 123

Using web-based tools we carried out a bioinformatic analysis of the SARS-CoV-2 glycoprotein 124 sequence, in order to identify novel B and T cell epitopes with potential to be used as vaccine targets. 125

In order to do so we followed the strategy shown in figure 1 , where we show the tools and parameters 126 chosen to carry out the analysis. 127

We carried out a literature review of studies reporting epitope mapping of the spike glycoprotein 129

form SARS-CoV-2 and were able to compile a total of 41 potential B cell epitopes (Supplementary 130 Table 1 ) that were identified through bioinformatic analysis by other research groups (20-23). By 131

using BepiPred 1.0 and 2.0 we predicted 101 epitopes from which 41 were selected based on their 132 score and surface accessibility. In total, we compiled 82 potential B cell epitopes (from our study and 133 previous reports) from which 14 were both predicted in this study and reported by other groups and 134

27 were novel epitopes predicted in this study. Epitopes that coincided with previously reported 135 epitopes or had overlapping residues, were merged into one peptide which covers all reported and 136

predicted epitopes and are shown in bold letters in Supplementary Table 1 229E) allowed us to identify conserved epitopes amongst these coronaviruses that could be target of 147 cross-reacting antibodies. We were able to identify 7 different epitopes that share certain identity 148 between the seven coronaviruses ( Table 1 ). Most of the conserved epitopes are situated on the heptad 149 repeat 1 (HR1) (Supplementary figure 1C) with some of them facing the inner part of the trimeric 150 structure ( Figure 2C ). Table 1 shows the sequences of the conserved peptides with the percentage of 151 identity between the SARS-CoV-2 sequence and the other six coronaviruses. Only one of the seven 152 peptides (VEAEVQIDRLITGRLQSL) showed a percentage of identity higher than 60% between 153 SARS-CoV-2 and all the other coronaviruses sequences. As expected, epitopes between SARS-CoV 154

and SARS-CoV-2 shared the highest identity percentages between coronaviruses. 155

Using the ElliPro and DiscoTope tools from the IEDB website we predicted potential discontinuous 156 epitopes on the SARS-CoV-2 spike glycoprotein. Prediction using ElliPro yielded 12 discontinuous 157 epitopes ( Figure 3A ) of which 3 have residues belonging to the RBD and residues belonging to the 158 NTD. A single epitope contains residues in the region of the fusion peptides (FP) and in HR1 ( Figure  159 3A). The remaining 8 epitopes have residues situated in the transitional region between the S1 and S2 160 subunits ( Figure 3A ). Three epitopes predicted by ElliPro contained residues from 2 different 161 monomers, these epitopes are shown in colours red, blue and green in figure 3A . In addition, one 162 epitope shown in yellow in figure 3A , contained residues from each of the 3 monomers from the 163 spike glycoprotein trimer, suggesting the presence of a highly antigenic region within the trimeric 164 structure. Prediction of conformational epitopes using DiscoTope 2.0 resulted in 967 surface residues 165 from which 55 were chosen based on a sensitivity of 0.47 and specificity of 0.75. The selected 166 residues are distributed mainly in 4 domains ( Figure 3B ). In particular, one residue (N282) belongs to 167 the NTD, and the RBD contains 28 of the predicted residues with 27 of these situated in the RBM 168 ( Figure 3B ). Within the S2 region, three residues (P793, I794 and P809) are located in the fusion 169 peptide (FP) and another three residues (N914, Y917 and E918) fall within the HR1. The predicted 170 residues are shown in Figure 3B , where predicted residues with a high specificity (91 to 100%) are 171

shown in red, the residues with medium specificity (86 to 90%) are shown in yellow and residues 172 with a low specificity (75 to 85%) are shown in blue. 173

From reports in the literature we compiled 107 peptide sequences reported to be CD8 and CD4 T cell 175 epitopes ( Figure 4A and Supplementary figure 2A) region, all groups from the Mexican population within capital cities across the country. Using these 184 parameters we were able to predict a total of 66 possible T cell epitopes ( Figure 4B and 185

Supplementary figure 2B) , from which 30 have predicted binding to MHC-I, 32 have predicted 186 binding to MHC-II and 4 are predicted to be promiscuous T cell epitopes (Supplementary Table 2 ). 187

Reported epitopes found in the literature can be found all throughout the spike glycoprotein structure 188 ( Figure 4A ). In contrast, predicted epitopes are present throughout the structure with the exception of 189 a noticeable gap in the transmembrane domain (TD) ( Figure 4B ). Through a multiple sequence 190 alignment we identified 38 epitopes ( Figure 4C and Supplementary figure 2C) that shared certain % 191 of identity between the SARS-CoV-2 spike glycoprotein and the other human coronaviruses CoV, MERS-CoV, HKU1, NL63, OC43 and 229E). world, more than one vaccine will be required and it's highly possible that first generation vaccines 206 will be far from perfect. In addition, we still lack a deep understanding of what is considered a 207 protective immune response with most vaccine candidates focusing on neutralising antibodies, 208 although the evidence suggests cellular immunity might play a critical role. 209

Through the literature review and epitope prediction exercises carried out in this project we were able 210 to compile 82 potential linear B cell epitopes in the spike glycoprotein which could explain cross-211 reactive responses reported in the literature. Twenty-seven novel epitopes were predicted, with the 212 majority of them situated in the RBD and the NTD ( Figure 2B ). Recent studies have reported the 213 identification of neutralising antibodies that target the NTD (29), therefore we consider the novel 214 epitopes predicted in this study require to be further investigated as potential neutralising targets. 215

Discontinuous B cell epitopes were also predicted in this study by using two different web-based 216 tools. Even though ElliPro and DiscoTope yielded the prediction of epitopes in similar regions of the 217 spike glycoprotein, there are limitations in the accuracy of these predictions given the nature of 218 conformational epitopes. As more experimental data is generated, predictions of conformational 219 epitopes for the SARS-CoV-2 spike glycoprotein will become more refined and precise. Despite the 220 limitations, we believe that investigating potential neutralising antibodies against the predicted 221 residues should be pursued. Given that coronaviruses have a latent pandemic potential we were 222

interested to see if amongst the epitopes compiled in this manuscript there were conserved epitopes 223 between the SARS-CoV-2 spike glycoprotein and other relevant human coronaviruses. We identified 224 only 7 linear B cell epitopes that share certain identity between the SARS-CoV-2 spike glycoprotein 225 and other coronaviruses. The percentages of identity between peptides ranged from 19 to 100%, with 226 only one epitope with at least 60% identity between SARS-CoV-2 and all the other coronaviruses. 227

Recent studies have shown that anti-spike antibodies generated in response to SARS-CoV infection 228 recognise the spike glycoprotein of SARS-CoV-2 and vice versa, suggesting antigenic similarities 229

between the spike glycoprotein of these two viruses. However, these cross reactive antibodies did not 230

show any neutralising activity against other than the virus that caused the infection (30). Given that 231 SARS-CoV and SARS-CoV-2 share the highest similarity it is highly unlikely that these antibodies 232 could have neutralising activity against any of the other human coronaviruses. Another study showed 233 that memory B cells from convalescent patients once infected with SARS-CoV, produce a repertoire 234 of monoclonal antibodies that cross-neutralise SARS-CoV-2 while they showed no binding to OC43 235 or MERS spike glycoproteins (31). A different report showed that antibody responses against 236 infection with seasonal human coronaviruses elicit neutralising antibodies against SARS-CoV-2, 237 however responses were measured short after infection occurred and therefore there is no information 238 about the potential longevity of such responses (32). All these observations show that cross-reactive 239 humoral responses between coronaviruses are plausible, however it is still not clear whether they are 240 robust enough to provide protection against infection and if they are long-lasting. 241

On the other hand a total of 66 potential T cell epitopes were predicted in this study, with 30 being 242 MHC-I restricted, 32 MHC-II restricted, and 9 predicted to be promiscuous T cell epitopes. central memory and effector memory phenotype, but more importantly mild cases generated higher 248 frequencies of multi-cytokine producing CD8+ T cells (34). Strong memory T cell responses specific 249

to SARS-CoV-2 have also been detected in samples from individuals who had mild or even 250 asymptomatic infections, interestingly some in the absence of antibody responses (33). A study by 251

Grifoni and collaborators reported T cells respond to stimulation with SARS-CoV-2 peptides in 252

samples collected prior the current pandemic started, suggesting infections with seasonal 253

coronaviruses elicit memory T cell responses that cross-react with SARS-CoV-2. Pending 254 experimental confirmation, our work provides a panel of 38 T cell epitopes that might be responsible 255

for these cross-reactive responses (Table 2) . Together these observations strongly support the 256 hypothesis that the role of cellular responses in controlling infection by SARS-CoV-2 might be as 257 important as antibody responses, and could provide protection in the absence of humoral responses. 258

In this context, the identification of potential protective T cell epitopes gains relevance in the design 259 of next generation SARS-CoV-2 vaccines. 260

In conclusion, we were able to identify T cell epitopes from the SARS-CoV-2 glycoprotein that were 261 found to have certain degree of identity between SARS-CoV-2 and the other human coronaviruses. 262

The percentages of identity for these T cell epitopes were considerably higher to those found for B 263 cell epitopes (Tables 1 & 2) . Experimental evidence suggests robust T cell responses are generated in 264 response to infection to SARS-CoV-2 and cross-reactive T cells circulate in the population prior 265 SARS-CoV-2 exposure. The contribution of these responses towards protection remains to be further 266 investigated in order to confirm our hypothesis. We hope that this manuscript will contribute to 267 understand immune responses elicited in response to infection, and highlight the potential role of T residues with a high specificity (91 to 100%) are shown in red, the residues with medium specificity 393 (86 to 90%) are shown in yellow and residues with a low specificity (75 to 85%) are shown in blue. 394 Tables  413   Table 1 . SARS-CoV-2 reported linear B cell epitopes identity (%) shared with other coronaviruses The datasets generated and analyzed for this study can be found in the bioRxv repository 417

An interactive web-based dashboard to track COVID-19 in real 285 time

A Review of Coronavirus Disease-2019 (COVID-19)

On the origin and continuing evolution of 289 SARS-CoV-2

Bats are natural reservoirs of SARS-291 like coronaviruses

SARS-CoV-2 cross-reactive epitopes 8

Coronavirus protective immunity is short-lasting. medRxiv

The time course of the immune response to 297 experimental coronavirus infection of man

Long-Term Persistence of IgG 300 Antibodies in SARS-CoV Infected Healthcare Workers

Structure, Function, and 303 Antigenicity of the SARS-CoV-2 Spike Glycoprotein

T cell responses to whole SARS 306 coronavirus in humans

T cell-mediated immune response to respiratory 308 coronaviruses

The EMBL-EBI search 311 and sequence analysis tools APIs in 2019

2018 update

NetSurfP-317 2.0: Improved prediction of protein structural features by integrated deep learning

ElliPro: a new 320 structure-based tool for the prediction of antibody epitopes

Reliable B Cell Epitope Predictions: 323 Impacts of Method Development and Improved Benchmarking

Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity 327

Properties of 329 MHC class I presented peptides that enhance immunogenicity

Developing a Fully-334 glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane

Prediction of T and B Cell Epitopes in the Proteome of SARS-CoV-2 for 337

Potential Use in Diagnostics and Vaccine Design

COVID-19 living paper: overview of 340 information available to support the development of medical countermeasures and interventions 341 against COVID-19

Drug and Vaccine Design against Novel Coronavirus (2019-nCoV) Spike Protein 343 through Computational Approach

COVIDep: a web-based platform for real-time 346 reporting of vaccine target recommendations for SARS-CoV-2

A Sequence Homology 349 and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Functional classification of 352 class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a 353 surprising degree of repertoire sharing across supertypes

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role 357 for CD8+ T cells

TepiTool: A Pipeline for Computational Prediction of T 360

Developing Covid-19 Vaccines at Pandemic Speed

A neutralizing human antibody 364 binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Cross-370 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pre-existing and de novo 373 humoral immunity to SARS-CoV-2 in humans

Robust T 376 cell immunity in convalescent individuals with asymptomatic or mild

The authors declare that the research was conducted in the absence of any commercial or financial 271relationships that could be construed as a potential conflict of interest. We would like to thank Guillermo Ramón Torres for kindly facilitating the use of PyMOL® software 282 in order to build the 3D models presented in this manuscript. 283

References 284